Filter By Industry
Filter By Tag

Newsroom

HOPE BIOSCIENCES, INC. Press releases

1 - 4 of 4 Press Releases

Campaign To Fight Staggering Anti-Cancer Drug Cost & Fund Drug Development Launched
Mar 27, 2017
The staggering cost of cancer treatment means only patients living in the wealthiest countries have access to the latest treatment options against cancer.

Dr. Michael Adam Joins Hope Biosciences To Oversee Pharmaceutical & Manufacturing Operations And Regulatory Affairs
Feb 15, 2017
HOPE BIOSCIENCES, INC. announced today that Dr. Michael Adam has joined the management team to oversee Pharmaceutical and Manufacturing Operations as well as Regulatory Affairs and Quality Assurance. Dr.

Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm
Feb 01, 2017
- High potency (at nanomolar concentration) against MERTK, a promising I-O target; - Overcomes AXL/c-MET mediated resistance to EGFR-directed therapies in NSCLC in vivo; - Ready for IND submission in 2018

Hope Biosciences Licenses nuc-Gemcitabine, A 'Trojan Horse' Anti-nucleolin-Gemcitabine Aptamer Drug Conjugate Against Cancer
Jan 23, 2017
HOPE BIOSCIENCES announced today that it has acquired the exclusive rights to develop and commercialize nuc-gemcitabine™ (APTA-12/HOPE-888) through a licensing agreement with AptaBio Therapeutics, a Korean pharmaceutical company.


HOPE BIOSCIENCES, INC. RSS Feed